Who

ARE WE?

AELMHU is a non-profit association, established in 2011 by a group of pharmaceutical and biotechnology companies, with a strong commitment to research, develop and commercialise innovative therapies to improve the quality of life of patients suffering from rare and ultra-rare diseases.

Our

MISSION

To contribute to improving the health and quality of life of people affected by rare diseases, giving visibility to the pathologies and highlighting research and treatments for them.

What do

YOU DO?

WE COLLABORATE WITH ORGANISATIONS

patients, public administrations and other stakeholders, with the aim of contributing our knowledge and experience in the treatment of rare diseases.

WE TRAIN AND INFORM

on the value of orphan and ultra-orphan drugs for the treatment of these pathologies.

WE GIVE VISIBILITY

to the special characteristics of rare and ultra-rare diseases

WE JOIN FORCES

and we support R&D to bring new orphan drugs to the market.

Bodies of GOVERNMENT

The supreme governing body of AELMHU is the General Assembly. This body is composed of all members in their own right and on an equal footing.

The association also has a Board of Directors, which is responsible for managing and representing the association.

The current members of the Board of Directors are:

BEATRIZ PERALES

President

Mª JOSÉ SÁNCHEZ

Vice President

JOSÉ LUIS MORENO

Secretary and member

SERGIO BULLÓN

Treasurer and member

IVAN SILVA

Member

The AELMHU technical team supporting the Board of Directors is led by:

MARIAN CORRAL

Executive Director

MEMBERS

AELMHU is made up of small and medium-sized pharmaceutical and biotechnology companies. The common denominator of all of them is their strong commitment to research into rare diseases and the search for innovative therapies to improve the quality of life of patients suffering from these pathologies.

Become a partner

Do you want to join AE ?